Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients

Mamdouh Ramadan, Mohamed El-Wakil, Shahera Shaaban
2020 Egyptian Journal of Medical Research  
The goal of this study is To assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 over expressed breast cancer. Fifty female patients have known to be HER2 over expressed breast cancer, recruited from clinical oncology clinic at Beni-Suef University hospital and from the insurance hospital at Beni-Suef city. This is retrospective study. This study was done within a six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a
more » ... d be considered a standard on completion of loco regional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS.
doi:10.21608/ejmr.2020.89043 fatcat:vudkay5mpbfn3au5geslq5h7bm